CClinicalTrials.gg
Not yet recruitingNCT07330765Total kneeUpdated Jan 9, 2026

Analgesic Efficacy of Pre-Operative Dose of Palmitoylethanolamide in Patients Undergoing Total Knee Arthroplasty

A Phase 1/2 interventional study of Effect of two different drugs on post operative pain after TKA in Total Knee Replacement, sponsored by Abdelrahman Gaber Sayed Elkhateeb. Not yet recruiting at 1 site in Egypt. Open to participants aged 40 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-09.

Sponsored by Abdelrahman Gaber Sayed Elkhateeb · Phase 1/2, Interventional, and Treatment

Phase
Phase 1/2
Study type
Interventional
Enrollment
1
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Study summary

Analgesic Efficacy of Pre-Operative Dose of palmitoylethanolamide in Patients Undergoing total Knee Arthroplasty, A Randomized Double-Blinded Controlled Trial.

Read the detailed description

Elective total knee arthroplasty (TKA) is the gold standard for management of arthritis-associated pain and disability in osteoarthritis patients who have failed non-operative treatment modalities Following TKA, patients experience severe pain mediated by multiple pathways Painful stimuli to the body are detected by the free endings of peripheral nerves called nociceptors . Pre-emptive analgesia is analgesia given before the onset of painful stimuli to prevent central sensitization of nervous system to subsequent stimuli that could increase pain Studies have shown that pre-emptive analgesia reduce immediate postoperative pain and also prevent the development of chronic pain by decreasing altered sensory processing .

Multi-modal analgesia is the rational approach to pain management since no single analgesia targets all types of pain

. Increasing evidence has shown that neuro-inflammation plays a key role in pain progression which is sustained by an imbalance within pro-inflammatory and pro-resolving mediators Acylethanolamines (NAEs) are a family of endogenous bio active lipids that regulate multiple processes including pain and inflammation . One of the most widely studied NAEs is the analgesic endocannabinoid compound, palmitoylethanolamide (PEA). Previous research has demonstrated the effectiveness of PEA on conditions characterized by chronic and/or neurological pain The aim of the study is to investigate the safety, tolerability and efficacy of doses of PEA on symptoms of post operative pain.

02

Conditions studied

  • Total Knee Replacement

Browse trials for

Keywords

  • Post operative pain
03

In context

Pain, Postoperative

5,093 studies on the registry are indexed under Pain, Postoperative; 1,140 are open to participants now.

This study's planned enrollment of 1 is below the median of 75 across 4,344 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

This is the only study on the registry with Abdelrahman Gaber Sayed Elkhateeb as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

Patients Undergoing Total Knee Replacement from 40 years old to 80 years old

Exclusion criteria

Exclusion Criteria

  • Rheumatoid Arthritis

    • History of Renal impairment
    • Any complications of surgery as( iatrogenic fractures -patient with low bone quality that needs long stem prosthesis -patient with depressed tibial plateau that needs graft )
    • Patients refused to be enrolled in the study
05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1 participant (estimated)

Study arms

  • Experimental
    Placebo effect on post operative pain after TKA

    The patient will be gaven an empty pill and we will score the pain postoperative and if it has effect on postoperative pain or not

    Drug: Effect of two different drugs on post operative pain after TKA

  • Experimental
    Palmetoyelethenolamide effect on post operative pain after TKA

    The patient will be gaven an pill containing palmytoiethenolamide and we will score the pain postoperative and if it has effect on postoperative pain or not

    Drug: Effect of two different drugs on post operative pain after TKA

Interventions

  • DrugEffect of two different drugs on post operative pain after TKA

    Effect of preoperative dose of palmetoyelethenolamide in post-op pain in patient undergoing Total Knee Replacement

    Also known as: Palmetoyelethenolamide, Placebo pill

06

What researchers measure

Primary outcomes

  1. Decrease post operative pain

    Visual Analog Scale (VAS) will be used at 6, 12, 24 hours post-surgery for assessment of Pain. Scale from one to ten Ten means patient in sever pain One means patient is well The higher the score the pain is severer

    Time frame: Frist 24 hours postoperative

07

Study locations

1 site
  • Assiut university
    Asyut, Assuit, Egypt
08

References and documents

Publications

  • https://pmc.ncbi.nlm.nih.gov/articles/PMC10053226/#:~:text=Palmitoylethanolamide%20(PEA)%2C%20a%20naturally,pain%2C%20although%20this%20remains%20controversial

Individual participant data

Plan to share: Undecided — It's an experimental study it will be shared if the outcomes of the study are valid to be shared

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07330765
Lead sponsor
Abdelrahman Gaber Sayed Elkhateeb
Responsible party
Abdelrahman Gaber Sayed Elkhateeb (Assistant lecturer, Assiut University) — Sponsor-investigator
First posted
Jan 9, 2026
Start date
Jan 13, 2026 (estimated)
Primary completion
Oct 13, 2027 (estimated)
Completion
Oct 13, 2027 (estimated)
Last update
Jan 9, 2026

Study contacts

Abdelrahman Gaber Elkhareeb, Resident
Contact
AbdElrahman.15235731@med.aun.edu.eg
201050081327

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion